In recent years, the practice of scientifically adapting human DNA has been advanced through the breakthroughs resulting from the National Institute of Health’s Human Genome Project. Through the careful adaption of DNA, researchers are advancing targeted options for treating serious illnesses, such as certain cancers. But these opportunities are also introducing important conversations regarding medical ethics and other risks.
We are pleased to offer deeper insights on this topic in our first whitepaper of the year titled “Gene Editing: CRISPR/Cas-9 and Beyond” authored by Medical Technology Risk Control Specialist Michael Campbell. In this whitepaper, Mike provides an overview of the methodology, reviews issues and concerns, and notes what is on the horizon for this emerging discipline.
We hope you enjoy this publication and invite you to browse our complete whitepaper library for additional technology-focused insights.